Repligen Exceeds Q4 & Full Year 2025 Revenue Guidance, Projects Strong 2026 Growth and Margin Expansion
summarizeSummary
Repligen Corporation reported robust financial results for the fourth quarter and full year 2025, surpassing the high end of its previous revenue and adjusted operating income guidance. This strong performance is expected to continue into 2026, with management forecasting 10-14% revenue growth and a significant 150 basis point expansion in adjusted operating margin. The positive outlook, driven by traction across its differentiated portfolio and strategic investments, suggests continued operational strength and improved profitability.
check_boxKey Events
-
Q4 2025 Revenue Beat
Reported fourth quarter revenue of $198 million, an 18% year-over-year increase, exceeding the high end of previous guidance.
-
Full Year 2025 Strong Performance
Achieved full year 2025 revenue of $738 million, up 16% year-over-year, with 16% organic non-COVID growth.
-
Positive 2026 Guidance
Forecasts full year 2026 revenue of $810 million to $840 million (10-14% growth) and 150 basis points of adjusted operating margin expansion.
-
Return to GAAP Profitability
GAAP net income turned positive for both Q4 ($13 million) and full year 2025 ($49 million), reversing losses from the prior year.
auto_awesomeAnalysis
Repligen Corporation reported robust financial results for the fourth quarter and full year 2025, surpassing the high end of its previous revenue and adjusted operating income guidance. This strong performance is expected to continue into 2026, with management forecasting 10-14% revenue growth and a significant 150 basis point expansion in adjusted operating margin. The positive outlook, driven by traction across its differentiated portfolio and strategic investments, suggests continued operational strength and improved profitability.
在该文件披露时,RGEN的交易价格为$137.29,交易所为NASDAQ,所属行业为Life Sciences,市值约为$76.2亿。 52周交易区间为$102.97至$175.77。 这份文件被评估为积极市场情绪,重要性评分为7/10。